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Abstract
Introduction
Literature data have shown that the consumption of dietary proteins may cause modulatory
effects on the host immune system, process denominated oral tolerance by bystander sup-
pression. It has been shown that the bystander suppression induced by dietary proteins can
improve inflammatory diseases such as experimental arthritis. Here, we evaluated the
effects of oral tolerance induced by ingestion of ovalbumin (OVA) on TNBS-induced colitis
in mice, an experimental model for human Crohn’s disease.
Methods and Results
Colitis was induced in BALB/c mice by instilling a single dose of TNBS (100 mg/kg) in etha-
nol into the colon. Tolerized mice received OVA (4mg/mL) dissolved in the drinking water for
seven consecutive days, prior to or concomitantly with the intrarectal instillation. Control
groups received protein-free water and ethanol by intrarectal route. We observed that either
the prior or concomitant induction of oral tolerance were able to reduce the severity of colitis
as noted by recovery of body weight gain, improvement of clinical signs and reduction of his-
tological abnormalities. The in vitro proliferation of spleen cells from tolerant colitic mice was
lower than that of control mice, the same as the frequencies of CD4+ T cells secreting IL-17
and IFN-γ. The frequencies of regulatory T cells and T cells secreting IL-10 have increased
significantly in mice orally treated with OVA. The levels of inflammatory cytokines (IL-17A,
TNF-α, IL-6 and IFN-γ) were lower in supernatants of cells from tolerant colitic mice,
whereas IL-10 levels were higher.
Conclusion
Our data show that the modulation of immune response induced by oral tolerance reduces
the severity of experimental colitis. Such modulation may be partially attributed to the
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Introduction
Recently, inflammatory bowel disease (IBD) has been receiving more attention from physi-
cians and researchers due to the increase in its incidence in human populations [1–5]. IBD
comprises a set of related diseases, collectively called Crohn’s Disease (CD) and Ulcerative
Colitis (UC), which origin has been attributed to the breakdown of tolerance to self-antigens
in the intestinal mucosa [6]. The mechanisms involved in these autoimmunities are diverse
and cannot be considered mutually exclusive. They may include a combination of factors
among which one can highlight the unbalanced production of cytokines and interleukins such
as interleukin (IL)-9 IL-10, IL-35, transforming growth factor (TGF)-β. Several other mole-
cules, transcription factors and receptors are associated with colitis, including Cytotoxic
T-Lymphocyte Antigen (CTLA)-4, Leukocyte Activation Gene (LAG) -3, indoleamine (IDO),
perforin/antagonists and Glucocorticoid-Induced Tumor Necrosis Factor Receptor (GITR)
[7–11].
Recent literature, however, emphasizes the role of Th17 cells in inflammatory diseases such
as colitis. T helper (Th) 17 cells and other IL-17-producing-cells play a crucial role in intestinal
inflammatory diseases. IL-17 together with IL-22 appear to be related to induction of colitis,
since these cytokines initiate and amplify the local inflammatory signs and promote the activa-
tion of regulatory mechanisms directly against the cells of the intestinal epithelium [12,13]. In
turn, IFN-γ induces the production of inflammatory cytokines by cells of the innate immune
system, contributing to an increased tissue inflammation seen in colitis [4,12,14,15]. Therefore,
modulation of Th17 and INF-γ-secreting cells may affect the inflammation in colitis.
On the other hand, IL-10 produced by macrophages and regulatory T cells may skew the
response into a regulatory one, leading to a reduction in inflammation [15]. In addition, sev-
eral results suggest that tolerogenic dendritic cells (DC) lead to the generation of induced regu-
latory T (Treg) cells (CD4+CD25+Foxp3+) and an increase in the number of lymphocytes
expressing the suppressor molecule CTLA-4 [16–19].
Accordingly, several studies have attempted to modulate the inflammatory response
observed in experimental colitis by the induction of a tolerogenic response [16,20–23]. Specifi-
cally, oral tolerance by dietary antigens administration is a tool to the modulation of the
immune system. The suppression of immune response on oral tolerance is due to the low
responsiveness of local or systemic immune system, triggered by such protein antigens [24–
28]. Despite the great interest in the subject, the effects of oral tolerance by bystander suppres-
sion in colitis are not yet fully understood [16,21,29,30].
The aim of this study was to evaluate the effects of oral tolerance on TNBS-induced colitis
in mice of BALB/c. Tolerance was induced by oral administration of ovalbumin (OVA) in the
previous and subsequent induction of colitis. Parameters as body weight, histology of target
tissues, cell proliferation, cytokine production and expansion of regulatory CD25+Foxp3+ T
cells and Th17 cells on spleen cell cultures were evaluated here. Our data suggested that oral
tolerance to OVA modulates the immune responses against TNBS in BALB/c mice by
bystander suppression. Suppression of the immune response is reflected in the increase in reg-
ulatory T cells and decreased production of pro-inflammatory cytokines that together
markedly ameliorated the severity of the colitis.
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Materials and Methods
Animals
SPF female BALB/c mice (four weeks old) were obtained from the Multidisciplinary Center
for Biological Research (CEMIB) of the University of Campinas (UNICAMP) Campinas, SP,
Brazil, and housed in plastic cages in groups of five. They were maintained in specific patho-
gen-free environment at 25˚C ±1 and photoperiod of 12/12 hours, and fed with autoclaved
Nuvilab CR-diet and water ad libitum for at least 4 weeks before being used in experiments.
The methods described in this manuscript were carried out in accordance with the ‘Guide for
the Care and Use of Laboratory Animals’, as promoted by the Brazilian College of Animal
Experimentation (COBEA), and was approved by the Ethics Committee for Animal Experi-
mentation of University of Campinas. (CEUA/UNICAMP. Protocol #3077–1). All experimen-
tal procedures were performed under proper anesthesia and all efforts were made to minimize
animal suffering. Mice general health was daily monitored for signs of inflammation such as
rectal swelling, rectal bleeding, soft stool or weight loss. On day 5 after TNBS instillation, all
mice were sacrificed by cervical dislocation after anesthesia with a mixture of ketamine (60
mg/kg, Ketalar; Pfizer) and xylazine (6 mg/kg, Rompun; Bayer) (i.p.).
Oral tolerance
The induction of oral tolerance to OVA was performed as described elsewhere [31] and
depicted in Fig 1. Briefly, 4mg/mL OVA (Rhoster Commerce and Industry Ltda, Vargem
Grande Paulista, SP, Brazil) was added to water supply of BALB/c mice for 7 consecutive days.
The control mice received protein-free water.
Induction of experimental colitis
Experimental colitis was induced in BALB/c mice according to indications of Neurath and col-
leagues [29,32]. Mice were anesthetized and instilled with 100 μL of 1 mg/mL TNBS (2,4,6—
Fig 1. Flowchart of the TNBS-induced colitis and oral tolerance design. Panel A: Previous oral
tolerance. Panel B: Concomitant oral tolerance.
doi:10.1371/journal.pone.0170205.g001
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trinitrobenzenesulfonic acid; Sigma, USA) solution in 50% ethanol by intrarectal route. Con-
trol animals received 100 μL of 50% ethanol (Fig 1).
Evaluation of clinical signs of colitis
All groups were weighed daily until sacrifice. Clinical signs such as diarrhea, rectal prolapse,
bleeding and cachexia were registered and assigned as scores, ranging from 0 to 2, with 0: no
change, 1: slight change, and 2: severe change.
Histological analysis
On 5 days after TNBS instillation, mice were euthanized and the distal portion of the large
intestines were removed and fixed with 4% paraformaldehyde. The pieces were cleared and
embedded in paraffin. The sections were stained with hematoxylin and eosin. For the histolog-
ical analysis, the sections were evaluated for the presence of folds, hemorrhage, infiltration of
leukocytes on two distal portions of the intestines (1 to 2 cm and 2 to 3 cm from the rectum).
The thickening of the wall of the colon was measured in micrometers in distal portions, with
Infinity Analyze Nikon H600L program (100X). A score ranging from 0 to 20 was assigned
[32,33].
Spleen cell proliferation
On day 5 after colitis induction, mice of all groups were sacrificed and spleens were aseptically
removed. The spleens were macerated individually and erythrocytes in cell suspensions were
lysed. Cells were pelleted at 200 g for 10 min and cell concentration was adjusted to 1 x 106
cells/mL in RPMI medium (Sigma, USA) supplemented with 10% fetal bovine serum (Culti-
lab). Cells were stained with 1.25μM Carboxyfluorescein diacetate succinimidyl ester (CFSE)
according to manufacturer’s instructions (Invitrogen, USA). To determine the maximum
uptake, aliquots of the cell suspensions stained with CFSE were fixed with 1% formaldehyde
and analyzed by flow cytometer. Stained cells were seeded at 4x105 cell/well in sextuplicate,
and Concanavalin A (ConA) was added to each well at final concentration of 2.5μg/mL. Plates
were incubated at 37˚C in humidified incubator, with 5% CO2 for 72 hours. After the incuba-
tion period, cells were fixed with 1% formaldehyde and proliferation was assessed in
CD4+CSFE+ cells by flow cytometer [34]. Acquisitions were performed with FACScalibur flow
cytometer (Becton-Dickinson) and analyzes were done with the FCS Express 5 Plus Research
Edition software (FCS Express Launcher). Results were expressed as proliferation index (fold
change) calculated in relation to control group. Cells not stained with CFSE were also cultured
in the presence of ConA and their supernatants were collected for dosage of cytokines.
Phenotypic profile of T lymphocytes
The frequencies of T CD4+CD25+ Foxp3+ (Treg cells), T CD4+IL17+, T CD4+IFNγ+ and T
CD4+IL-10+ cells in the cultures were assessed by flow cytometer. Briefly, cell suspensions
were washed and initially stained with anti-CD4-PE (Clone GK1.5) and anti-CD25-FITC
(Clone 7D4). Following, cells were permeabilized by the addition of fixation/permeabilization
buffer (Cytofix / Cytoperm fixation/permeabilization kit, Becton-Dickinson, BD) and stained
with anti-Foxp3-APC (clone FJK-16S), anti-IL-17-APC (clone eBIO17B7) or Alexa Fluor 647
(Clone TC11-18410), anti-IFNγ-APC (Clone XMG1.2), IL-10-APC (clone JESS-16E3) accord-
ing to manufacturer’s instructions. Acquisitions were performed with FACScalibur flow
cytometer and analyzes were done with the FCS Express 5 Plus, Research Edition software.
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Th1/Th2/Th17 cytokines determination
IL-2, IL-4, IL-6, IL-10, IL-17A, IFN-γ and TNF-α were quantified in culture supernatants of
spleen cells by flow cytometry by using Multiplex CBA kit (BD Cytometric Bead Array Th1/
Th2/Th17, San Diego, USA) according to manufacturer’s instructions. Cells were acquired in
FACSCalibur cytometer and analyzed with FCAP Array TM Software Version 3.0 (BD).
Statistical analysis
The statistical analysis was performed using GraphPad Prism 5 (GraphPad Software, San
Diego, CA, USA). The statistical significance of differences between control and experimental
groups was determined by one-way ANOVA, followed by multiple comparisons Bonferroni’s
test. Results were expressed as mean ± Standard Error Mean (SEM). Values were considered
significant at P> 0.05. All data are representative of at least three independent experiments.
Results and Discussion
The gastrointestinal tract is in constant contact with dietary proteins, commensal microorgan-
isms and potentially pathogenic microorganisms. To ensure the maintenance of homeostasis
of the organism, the immune system of the intestinal mucosa must be able to tolerate antigens
from diet and commensal microbiota and generate protective responses against harmful anti-
gens. The ability of intestinal mucosa-associated lymphoid tissue (MALT) to suppress systemic
immune response against ingested proteins is known as oral tolerance. Oral tolerance has been
demonstrated in various experimental models and for different antigens [20,24,26,35,36].
Nowadays, other routes are under evaluation in order to develop oral tolerance strategies for
immunotherapy. In this sense, eye-induced tolerance is a promising therapeutic tool in the
treatment of complicated autoimmune diseases such as CIA [37,38] or EAE [39–41]. Several
tolerance protocols are being proposed for controlling inflammatory manifestations, in partic-
ular autoimmune diseases such as colitis [42–48].
The TNBS-induced colitis is a widely used experimental model for the study of inflamma-
tory bowel disease (IBD), since their clinical symptoms and immunological response are simi-
lar to those observed in human intestinal diseases [33,49–55]. BALB/c mice are often used for
induction of colitis by TNBS administration because they develop a milder disease than SJL
strain, but with significant clinical and immunological signals [49,54,56].
Data presented here show that the consumption of OVA, either prior or concomitant to
colitis induction, led to the reduction of the weight (Fig 2A) and of typical clinical signs of
TNBS-induced colitis, such as diarrhea, rectal prolapse, bleeding and cachexia (Fig 2B). The
subsequent intraperitoneal challenge with OVA led to decreased levels of serum antibodies in
animals fed protein, indicating a systemic effect of oral treatment (Fig 2C).
To evaluate the possible effects of OVA consumption on the intestinal mucosa, the distal
segments of the large intestine of mice from all groups were collected on the fifth day after the
induction of colitis and evaluated histologically. As summarized in Fig 3, the oral treatment
with OVA prior to or concomitant with induction of colitis was able to partially preserve the
integrity of the colonic tissue of mice with colitis. This can be observed by the significant
reduction of histological changes (bends, hemorrhage and leukocyte infiltration) in the tissues
of animals tolerized to OVA (Fig 3A and 3B) as well as the preservation of the wall thickness of
the colon (Fig 3C) compared to the control animals. Together, these results indicate a possible
bystander suppression of the immune response in mice tolerized with OVA, able to alter the
course of experimental disease.
Previous studies conducted in our laboratory showed that it is possible to induce oral toler-
ance to OVA in animals that exhibit a normal repertoire of receptors to the target antigen
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[31,57]. Several mechanisms seem to be involved in the induction of tolerance, including
anergy, clonal deletion and induction of Treg cells [24,58–61]. Weiner and colleagues
[22,48,62] suggested that the mechanisms that operate in the induction of oral tolerance are
directly related to the antigen administration regimen. Thus, administration of high doses of
antigens at once would lead to clonal deletion or anergy, while multiple doses of antigen in low
concentrations would be capable of promoting the suppression mediated by suppressor/regu-
lators T cells. However, Siewert et al [63] found a high rate of Foxp3+ T cells from oral tolerant
mice that had been induced by high dose of antigen. This finding indicates that higher doses of
antigen did not lead to clonal deletion, but the generation of suppressive responses associated
with oral tolerance. Some cytokines, such as granulocyte macrophage colony stimulating factor
Fig 2. OVA intake improves the severity of TNBS-induced colitis in mice. For induction of tolerance an
OVA solution (4mg / ml) was provided in drinking water to BALB/c mice (n = 5) for seven consecutive days,
either 3 or 10 days before colitis induction. The experimental colitis was induced in BALB/c mice by intrarectal
instillation of TNBS in 50% ethanol (1 mg / mL, 100 μL). Two control groups were included: mice that received
protein-free water and were instilled with either ethanol (white bar) or TNBS (light gray bar). Panel A:
Temporal changes in body weight, in percentage. All mice were weight daily and the weight alteration was
represented by percentage in comparison with the mean initial value found on day 1 and represented as
100%. Body weights in orally treated mice were significantly higher than in non-tolerant mice. Panel B: Clinical
signs were evaluated for the presence of diarrhea, rectal prolapse, bleeding and cachexia, assigning a score
ranging from 0 to 2, with 0: no change, 1: slight change, and 2: severe change. Panel C: Oral tolerance to
OVA modulates antibody production. Oral tolerance and experimental colitis was induced as illustrated in Fig
1. Five days after TNBS instillation, mice of all groups were immunized with OVA (10 mg) in aluminum
hydroxide (1 mg) by intraperitoneal route, and 14 days later challenged i.p. with 10mg OVA in saline solution.
On day 21, sera were collected, diluted 1: 100 to 1: 12,800 and tested by ELISA for anti-OVA antibodies (A)
and anti-TNP (B). Values are means ± SEM sum of the optical densities (O.D.) Data are representative of
three independent experiments (n = 5). ANOVA followed by Bonferroni post-test were used to determine
statistical significance (p <0.05).
doi:10.1371/journal.pone.0170205.g002
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(GM-CSF) can modulate DC towards a tolerogenic profile acting as an anti-inflammatory or
regulatory modulator in autoimmune diseases, depending on its dose and the presence of
other cytokines. Tolerogenic DCs can increase the frequency and function of regulatory T-
cells [64–69].
Data from our laboratory have shown that continued ingestion of low doses of OVA can
interfere with the phenotypic distribution of intraepithelial lymphocytes (IELs) in the small
intestine of wild type BALB/c. After ingestion of OVA, BALB/c mice showed increased fre-
quency of CD4+Foxp3+ regulatory T cells and increased expression of regulatory cytokines on
IELs [70].
Fig 3. The oral tolerance to OVA changes histopathological features in the large intestine of mice with
TNBS-induced colitis. BALB / c mice were exposed to the treatments described in Fig 2 and sacrificed 5
days after induction of colitis. Distal part of large intestine was collected and fixed in paraffin for histological
processing. Panel A: Histological sections of 5μm were stained with hematoxylin and eosin and examined by
light microscopy (200X). Panel B: Sections were assessed for the presence of folds, hemorrhage, and
infiltration of leukocytes at two distal portions of the intestines (1 to 2 cm and 2 to 3 cm from the rectum),
assigning a score ranging from 0 to 20. Panel C: Thickening of the colon wall, measured in micrometers in two
distal portions was analyzed with Infinity Analyze Nikon H600L program (100X). Two independent analyzes
were performed.
doi:10.1371/journal.pone.0170205.g003
Oral Tolerance Induced by OVA Intake Ameliorates TNBS-Induced Colitis in Mice
PLOS ONE | DOI:10.1371/journal.pone.0170205 January 18, 2017 7 / 16
To investigate the systemic effects of OVA intake on cellular immune response of colitic
mice induced by TNBS, spleen cells were collected on the fifth day after the induction of colitis
and assessed for their proliferative capacity and for the expansion of CD4+ T lymphocytes with
regulatory and effector profiles. The results summarized in Fig 4 and in S1 Fig show that the
proliferation of spleen cells from mice fed with OVA was significantly lower than that observed
in cultures of spleen cells from the control group (Fig 4A), whereas the frequency of Treg cells
(TCD4+CD25+ Foxp3+) and expression of Foxp3 was higher in cultures of cells from tolerized
mice (Fig 4B and 4C). It was also observed an increase in the frequency of CD4+IL-10+ T cells in
spleen cell cultures of mouse fed with OVA (Fig 4D) as well as a reduced frequency of
CD4+IFN-γ+ T cells and CD4+IL17+ T cells (Fig 4F and 4H) compared with non-tolerant group.
Assessment of cytokines in the supernatants of spleen cells revealed no statistically signifi-
cant differences in IL-2 secretion in the experimental groups (Fig 5A), but showed an increase
in IL-10 levels (Fig 5B) and reduction in levels of IFN-gamma (Fig 5C) and IL-17 (Fig 5D) in
the spleen cell cultures from mice tolerized with OVA compared to the non-tolerant group.
The results presented here are consistent with data recently obtained by our group in the
experimental model of arthritis [34].
Corroborating our data, the literature shows that regulatory T cells may play an important
role in autoimmune diseases [15,50,71–75] and the expansion of this population can aid in the
control of clinical manifestations [16,76–78]. Moreover, Th17 cells have a potential role in the
induction of inflammatory bowel disease and its reduction must also contribute to the
improvement of the clinical picture in several autoimmune conditions [12,76,79,80].
It is already known that CD4+CD25+Foxp3+ cells on the intestinal mucosa seems to be able
to induce local generation of Th3 cells secreting TGF-β (LAP+), type 1 regulatory T (Tr1) cells
and CD8+T reg cells [48,81]. These regulatory T cells generated in the intestine migrate to sec-
ondary lymphoid organs such as Peyer’s patches and mesenteric lymph nodes, which inhibit
the generation of nonspecific effector cells, by a mechanism known as bystander suppression
[22,82]. In addition, the imbalance between proinflammatory and anti-inflammatory cyto-
kines released by the intestinal mucosa determines the intensity and duration of the inflamma-
tory response seen in experimental colitis [14,15,33,83–86].
Data from our laboratory has shown that it is possible to protect mice against experimental
arthritis (CIA) by oral tolerization with OVA as a preventive or therapeutic intervention,
although the antigens involved in tolerization and triggering the disease had been adminis-
tered independently [34].
An increased frequency of both CD4+FoxP3+ and CD4+ IL10+ lymphocytes was also
observed after in vitro restimulation of spleen cells from tolerized arthritic animals. These
results, however, as well as those of Vaz and colleagues [87–90] show indirect effects of oral tol-
erance that do not fit perfectly in bystander suppression model.
By definition, the bystander suppression occurs when the immune response to a particular
epitope suppresses the response to another epitope administered concurrently or immediately
after the first one. The effects of bystander suppression is related to the secretion of cytokines
such as TGF-β, IL-4 and IL-10, and by the action of regulatory T cells [42,91,92].
Interventions leading to bystander suppression may be of great interest in autoimmunity
regulation. Thus, the suppressive response initiated by mucosal administration of dietary pro-
teins associated with self-antigens has been gaining ground as a preventive or therapeutic
intervention proposed for autoimmune diseases [24,42,48]. In this respect, several authors
have shown that the oral tolerance to dietary antigens may prevent or inhibit the progression
of systemic or organ-specific autoimmune diseases [34,35,93]. In this regard, data from our
and others laboratories have shown that it is possible to reduce the immune response to a dif-
ferent antigen from that used to induce oral tolerance, even if this antigen is administered
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Fig 4. The oral tolerance to OVA alters the proliferative response and cytokine producing cells from
mice with TNBS-induced colitis. The induction of tolerance and colitis was performed as described in Fig 2.
Mice were sacrificed five days after TNBS instillation. Spleens were aseptically removed; cells were labeled
with CFSE and cultured at a concentration of 2x106 cells / ml in the presence of Concanavalin A (ConA; 2,5μg
/ ml) for 72 hours at 37˚C and 5% CO2. Panel A: Spleen cell proliferation. Cells were fixed in 1% formaldehyde
and the readings performed in flow cytometer (FACSCalibur, BD). Proliferation was calculated using the
software FCS Express and represents the inverse of the ratio of the fluorescence exhibited by the cells after
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several days after ingestion of tolerogen and parenteral challenge with tolerated antigen
[34,38]. Recent work from Vaz group have shown that there is an expansion of regulatory T
CD4+Foxp3+ and T CD4+LAP+ non-specific cells in the early stage of parenteral exposure to
the antigen used in the oral treatment, phenomenon that is not seen in non-tolerant animals
subjected to the same treatment [94]. Similarly to what we have shown with our work, other
authors have demonstrated that increased IL-10 production correlates with the ability to
reduce inflammatory responses associated with human and experimental colitis [95,96].
72 hours of culture and those immediately after labeling with CFSE. The cell frequency (Panel B) and the
mean fluorescence intensity (MFI) of T regulatory CD25+Foxp3+ cells (Panel C), and the frequency of
cytokine producing cells (Panels D-I) were monitored within the CD4+ T cell gate. The values correspond to
the mean ± S.E.M. of two independent experiments (n = 5). ANOVA followed by Bonferroni a posteriori test
was used to determine statistical significance.
doi:10.1371/journal.pone.0170205.g004
Fig 5. The oral tolerance to OVA alters cytokine levels in supernatants of ConA-stimulated spleen
cells from mice with TNBS-induced colitis. Cultures of spleen cells were carried out as described in Fig 4.
Cytokine levels were evaluated in the culture supernatants by using the CBA Multiplex kit (Cytometric Bead
Array Th1 / Th2 / Th17, BD) and readings were performed in a flow cytometer (FACSCalibur, BD). Cytokine
concentrations were determined using the array FCAP TM Version 3.0 Software (BD). Results were
expressed as means ± S.E.M. obtained from two independent experiments (n = 5).ANOVA followed by
Bonferroni a posteriori test was used to determine statistical significance.
doi:10.1371/journal.pone.0170205.g005
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Conclusions
Our results indicate that the development of oral tolerance to OVA was able to reduce the
signs and the immune response in TNBS-induced colitis. The immunomodulation observed
can be attributed to the expansion of regulatory T cells and IL-10 producing cells, by a mecha-
nism known as bystander suppression. Further studies are in progress to evaluate the role of
dendritic cells in the protection afforded by oral tolerance in this colitis model.
Supporting Information
S1 Fig. Oral tolerance reduces the proliferation of T lymphocytes, increases the proportion
of CD25+Foxp3+Tregs and reduces IL-17-and INF-γ- producing-T cells on colitic mice.
Five days after the TNBS instillation, leukocytes were harvested from spleens of mice that
received OVA by oral route, as described in Fig 2. Leukocytes from spleens of naïve and
untreated TNBS mice were used as controls. The spleen cells were stained with CFSE and cul-
tured at a concentration of 2x106 cells / mL in the presence of Concanavalin A (ConA; 2,5μg/
mL) for 72 hours at 37˚C and 5% CO2. CFSE: Cells were fixed in 1% formaldehyde and the
readings performed in flow cytometer (FACSCalibur, BD). Cell proliferation was determined
using flow cytometry and assessed by fluorescence decay of the probe in the gate of CD4+ cells.
The frequency of CD25+ Foxp3+ Tregs in the different groups was evaluated in the gate of
CD4+ cells. IFN-γ-, IL-10-, and IL-17-producing cells were evaluated in the gate of CD4+ cells
as well. Histograms and plots are derived from a representative animal from two independent
experiments (n = 5/each assay).
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